QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NASDAQ:ICLR

ICON Public Stock Forecast, Price & News

$171.87
-1.13 (-0.65 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$171.33
Now: $171.87
$177.58
50-Day Range
$173.00
MA: $205.54
$220.96
52-Week Range
$104.28
Now: $171.87
$223.62
Volume1.27 million shs
Average Volume439,389 shs
Market Capitalization$9.22 billion
P/E Ratio28.65
Dividend YieldN/A
Beta0.91
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.
ICON Public logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000
Employees16,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.81 billion
Cash Flow$7.10 per share
Book Value$30.91 per share

Profitability

Net Income$373.99 million

Miscellaneous

Market Cap$9.22 billion
Next Earnings Date4/28/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

48th out of 1,968 stocks

Commercial Physical Research Industry

1st out of 42 stocks

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -
$171.87
-1.13 (-0.65 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ICON Public (NASDAQ:ICLR) Frequently Asked Questions

Is ICON Public a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICON Public stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICLR, but not buy additional shares or sell existing shares.
View analyst ratings for ICON Public
or view top-rated stocks.

What stocks does MarketBeat like better than ICON Public?

Wall Street analysts have given ICON Public a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ICON Public wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ICON Public?

ICON Public saw a decrease in short interest during the month of January. As of January 29th, there was short interest totaling 670,900 shares, a decrease of 26.9% from the January 14th total of 918,200 shares. Based on an average trading volume of 201,400 shares, the days-to-cover ratio is presently 3.3 days. Currently, 1.3% of the shares of the company are short sold.
View ICON Public's Short Interest
.

When is ICON Public's next earnings date?

ICON Public is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for ICON Public
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) posted its quarterly earnings results on Tuesday, February, 23rd. The medical research company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.83 by $0.07. The medical research company had revenue of $760.23 million for the quarter, compared to analysts' expectations of $750.16 million. ICON Public had a net margin of 11.95% and a trailing twelve-month return on equity of 21.42%. ICON Public's revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $1.83 earnings per share.
View ICON Public's earnings history
.

How has ICON Public's stock price been impacted by COVID-19 (Coronavirus)?

ICON Public's stock was trading at $152.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ICLR stock has increased by 12.7% and is now trading at $171.87.
View which stocks have been most impacted by COVID-19
.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of 8.10-8.50 for the period, compared to the Thomson Reuters consensus estimate of $7.94. The company issued revenue guidance of $3.2-3.3 billion, compared to the consensus revenue estimate of $3.16 billion.

What price target have analysts set for ICLR?

12 equities research analysts have issued twelve-month price objectives for ICON Public's shares. Their forecasts range from $140.00 to $280.00. On average, they anticipate ICON Public's stock price to reach $198.18 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts' price targets for ICON Public
or view top-rated stocks among Wall Street analysts.

Who are ICON Public's key executives?

ICON Public's management team includes the following people:
  • Dr. Steven A. Cutler, CEO & Director (Age 61, Pay $2.31M)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 42, Pay $900k)
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 46)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas N. O'Leary, Chief Information Officer
  • Mr. Simon Holmes, Exec. VP of Investor Relations & Corp. Devel. (Age 54)
  • Ms. Niamh Murphy, Director of Corp. Communications
  • Mr. Joe Cronin, Chief HR Officer
  • Ms. Dana Lynn Poff, Exec. VP of Program Management
  • Dr. Gary Curtis, Sr. VP of Global Clinical Pharmacology

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public CEO Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among ICON Public's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ICON Public's key competitors?

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), The Walt Disney (DIS), The Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lord Abbett & CO. LLC (0.21%), Todd Asset Management LLC (0.19%), Kornitzer Capital Management Inc. KS (0.16%), Globeflex Capital L P (0.12%), Captrust Financial Advisors (0.05%) and Knights of Columbus Asset Advisors LLC (0.04%).

Which institutional investors are selling ICON Public stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Knights of Columbus Asset Advisors LLC, Lord Abbett & CO. LLC, Intrepid Capital Management Inc., Dorsey Wright & Associates, Private Trust Co. NA, Globeflex Capital L P, and We Are One Seven LLC.

Which institutional investors are buying ICON Public stock?

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Todd Asset Management LLC, Handelsbanken Fonder AB, Kornitzer Capital Management Inc. KS, FDx Advisors Inc., Fayez Sarofim & Co, Captrust Financial Advisors, Fieldpoint Private Securities LLC, and Sowell Financial Services LLC.

How do I buy shares of ICON Public?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $171.87.

How much money does ICON Public make?

ICON Public has a market capitalization of $9.22 billion and generates $2.81 billion in revenue each year. The medical research company earns $373.99 million in net income (profit) each year or $6.88 on an earnings per share basis.

How many employees does ICON Public have?

ICON Public employs 16,000 workers across the globe.

What is ICON Public's official website?

The official website for ICON Public is www.iconplc.com.

Where are ICON Public's headquarters?

ICON Public is headquartered at SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000.

How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.